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and EPO doses in a regression of AUC on those two vari-
ables, baseline hemoglobin, and tumor type. Studies were
frequency-weighted by the number of subjects. DCRs
with conﬁdence intervals were calculated using a Monte-
Carlo approach. Similar regressions were conducted 
to compare EPO three-times-weekly (TIW) with DARB
once-weekly (QW) and DARB every-other-week (Q2W)
and to compare EPO QW with DARB QW and DARB
Q2W. RESULTS: The regression suggests a DCR of 166
(95% CI: 110–253). The comparison of EPO TIW to
DARB QW and DARB Q2W yields DCRs of 180
(107–243) and 170 (101–233), respectively. The com-
parison of EPO QW to DARB QW and DARB Q2W
results in DCRs of 116 (-16–185) and 173 (146–196).
CONCLUSION: The DCR of 260:1 estimated for
payment purposes is somewhat greater than the DCRs
estimated based on AUC.
PCN7
CERVICAL CANCER SCREENING IN THE
PHILIPPINE SETTING:A COST-EFFECTIVENESS
ANALYSIS
Ngelangel CA1, Limson GM2, Fajutrao LB1, Cordero CP1,
Javelosa MA1, Festin MR1, Ramiro LS1, Llave CL2,
Abelardo AD1
1University of the Philippines Manila, Manila, Philippines;
2UP-PGH, Manila, Philippines
OBJECTIVE: Cervical cancer is preventable. However in
the Philippines, cervical cancer incidence remain signiﬁ-
cant with an overall survival rate of 44% in 5 years and
about 10/100,000 women dying after 5 years. Limited
resources, insufﬁcient screening infrastructure and inade-
quate treatment services have all led to an inability of less-
developed countries like the Philippines to implement 
an extensive cytology-based cervical cancer screening
program. Our objective is to identify and recommend a
cost-effective approach towards early detection of pre-
cursor lesions and early stage cervical cancer for the
Philippines. METHODS: This economic evaluation inves-
tigated four screening methods namely: acetic acid eval-
uation (AA), magniﬁed acetic acid visualization (MAA),
Pap smear using spatula + cotton swab (SS) and Pap
smear using a cervix brush (CB). It was undertaken 
concurrently with a standard criterion study involving a
nationwide sample of 9 secondary and tertiary hospitals,
5 community health centers and their catchment areas.
Cost per woman screened, cost per precursor/early 
cancer lesion detected, and cost per life saved in 5 years
were calculated using a societal perspective, 8% discount
rate and 1998 as base year. RESULTS: Cost per woman
screened is highest for CB and lowest for AA, at both 
hospital (CB = 631.61PHP/15.44USD; SS = 607.52PHP/
14.86USD; MAA = 478.80PHP/11.71USD; AA =
476.31PHP/11.65USD) and health center settings (CB =
425.34PHP/10.40USD; SS = 401.24PHP/9.81USD; MAA
= 271.52/6.64USD; AA = 270.05PHP/6.60USD). Cost per
precursor/early cancer lesion detected among 100,000
women screened is highest for SS and lowest for 
MAA (SS = 1,641,945.90PHP/40,152.25USD; CB =
1,289,000PHP/31,521.29USD; AA = 149,783.02PHP/
3,662.80USD; MAA = 116,515.82PHP/2,849.28USD).
Cost per life saved is lowest for MAA and highest for SS
(MAA = 6,191.88PHP/151.42USD; AA = 6,561.65PHP/
160.46USD; CB = 7,685.69PHP/187.95USD; SS =
8,921.00PHP/218.15USD). Variations in incidence of
precursor/early cervix cancer lesions, sensitivity of differ-
ent screening methods, target population coverage and
discount rate did not change the results of cost per life
saved due to cervical screening. CONCLUSION: Acetic
acid visualization of the cervix (with or without magniﬁ-
cation) is the cervical cancer screen method of choice for
the Philippines.
CANCER—Economic Outcomes
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OBJECTIVE: While results from several surveys of oncol-
ogy patients have found that depression is more preva-
lent among cancer patients than the general population,
few retrospective studies have been conducted to conﬁrm
these ﬁndings. This study compares rates of depression
among prostate cancer patients with controls, and exam-
ines the incremental burden of depression on healthcare
expenditures. METHODS: The study population con-
sisted of 2356 newly diagnosed prostate cancer patients
in 1999 or 2000 in the MarketScan database. A randomly
selected matched (age, insurance type, and geographic
region) group of non-cancerous males were selected as
controls (n = 7,495). Patients were followed for 12
months and classiﬁed as having depression if they had any
inpatient or outpatient claims with a depression diagno-
sis. Chi-square tests were used to compare depression
rates, as well as to investigate if cancer treatment regimen
was associated with increased risk of depression. Expen-
ditures accumulated during the study period were 
compared among prostate cancer patients using 
Mann-Whitney U-tests. RESULTS: The mean age of the
study population was 68 years and over half (58%) of
the patients had Medicare coverage. The rate of depres-
sion among prostate cancer patients was approximately
twice that of the matched non-cancerous population
(2.97% vs. 1.83%, p = 0.0008). Prostate cancer patients
with depression had higher mean inpatient ($14,031 vs.
$7,345, p = 0.0183), outpatient ($8,807 vs. $8,041, p =
0.0434), drug ($2,868 vs. $1,601, p < 0.0001), and total
($30,220 vs. $21,415, p = 0.1125) expenditures than
prostate cancer patients without depression. Treatment
regimen was not a factor in depression status. CON-
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CLUSIONS: Consistent with survey ﬁndings, prostate
cancer patients were signiﬁcantly more likely to be diag-
nosed with depression compared to cancer free indi-
viduals. Cancer patients with depression accumulated
substantially higher expenditures than those without
depression. Improved depression screening and treatment
may lead to reduced healthcare costs and better quality-
of-life for cancer patients.
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OBJECTIVES: Variations in disease treatment and 
costs for US Colorectal Cancer (CRC) patients may be
explained by factors beyond characteristics of disease and
treatment. Patient characteristics may impact CRC treat-
ment and costs. The aim of the study is to investigate
whether patient characteristics such as payor, gender, and
age impact inpatient health care resource use and costs
for US CRC patients. METHODS: Primary study end-
points—hospital length of stay (LOS) and average daily
charges (ADC) among CRC patients were examined using
data from Health Care Utilization Project (HCUP)
Nationwide Inpatient Sample. Hospital discharges from
1993–1999 with principal discharge diagnosis of CRC
were included. All charges were expressed in 2000 US
dollars. Ordinary least square (OLS) models with log
transformation of LOS and ADC were developed. Covari-
ates were: gender, primary payor, age, year, and teaching
hospital. Disease-speciﬁc risk factors were also included
as potential confounders. RESULTS: We identiﬁed
213,875 CRC discharges. The mean LOS and ADC for
the reference groups were: 9.9 days and $2878 for male;
8.5 days and $2944 for HMO; 9.9 days and $2875 for
patients aged £54 years; 9.9 days and $2775 for non-
teaching hospital; and 11.5 days and $2589 for the year
1993. Semi-log OLS models, after controlling for other
covariates, indicated that female, Medicare, Medicaid,
self-pay, older people, and teaching hospital were associ-
ated with longer LOS (P < 0.0001); female, Medicaid,
Medicare, self-pay were associated with lower ADC,
while teaching hospital was associated with higher ADC
(P < 0.0001). Adjusted LOS declined at an annual rate of
3.7%, while ADC grew annually at 2.5%. CONCLU-
SIONS: Patient characteristics contributed to the varia-
tion of inpatient resource use for CRC patients. This
association provides health care policy decision-makers
information regarding treatment practices. Further re-
search should examine whether the association is ob-
served for other tumors and disease areas.
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OBJECTIVE: To determine health care resource utiliza-
tion and costs over ﬁve years among Veterans Adminis-
tration (VA) patients with cancer of the sigmoid colon.
METHODS: This retrospective study was limited to
veteran patients in New Mexico diagnosed between 1995
and 2000. Demographic information and data for out-
patient medications, imaging, chemotherapy, hospitaliza-
tions, number of clinic visits, and number of physician
visits were collected using VA databases. Costs applied
for all services other than outpatient medications and
chemotherapy were based upon 2001 Medicaid reim-
bursement values. Drug costs were based upon 2001 VA
prices. RESULTS: There were 46 total patients (45 male)
identiﬁed and data for years 2–5 was available for 35, 21,
19, and 11 patients respectively. The mean age was 72
years (+/-7.78), with a range of 49–87. Twenty-two
(48%) patients were in Stage 3 or 4, with lymph node
involvement and/or metastases, at ﬁrst diagnosis. The
mean resource utilization per patient was greatest in year
1 ($8,269 ± 7,434), followed by year 2 ($2,792 ± 4,935),
then year 5 ($1,496 ± 2,759). The top three cost drivers
for years 1 through 3 were hospitalization, chemother-
apy, and clinic visits versus hospitalization, imaging, and
clinic visits for years 4 and 5. The mean costs for treat-
ing Stage 3 or 4 patients were signiﬁcantly higher (p <
0.05) for years 1 and 5, year 1: ($10,959 +/- 9,481 versus
$5,867 +/- 3,641) and year 5: ($6,117 +/- 4,688 versus
$470 +/- 495). CONCLUSION: This initial economic
analysis helps identify costs and costs drivers in the treat-
ment of cancer of the sigmoid colon. The study can serve
as a model for data collection processes in the VA regard-
ing direct medical costs of cancer of the sigmoid colon.
With additional data, pharmacoeconomic modeling
research regarding prevention strategies and/or screening
methods could be performed.
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OBJECTIVES: Letrozole (Femara) offers increased life
expectancy with tolerable side effects for the management
of advanced breast cancer. The budget and population
